QQ客服 官方微博 反馈留言

	SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3 beta/beta-Catenin Signaling Axis
	Dai, Shuang; Yan, Yuanliang; Xu, Zhijie; Zeng, Shuangshuang; Qian, Long; Huo, Lei; Li, Xuejun; Sun, Lunquan; Gong, Zhicheng*
刊名	Frontiers in pharmacology
	2018
卷号	8期号:JAN页码:960
关键词	Akt signaling SCD1 glioblastomas resistance temozolomide
ISSN号	1663-9812
DOI	10.3389/fphar.2017.00960
URL标识	查看原文
WOS记录号	WOS:000419350200001
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3336978
专题	中南大学
作者单位	1.[Yan, Yuanliang 2.Xu, Zhijie 3.Dai, Shuang 4.Gong, Zhicheng 5.Zeng, Shuangshuang 6.Qian, Long] Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.
推荐引用方式 GB/T 7714	Dai, Shuang,Yan, Yuanliang,Xu, Zhijie,et al. SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3 beta/beta-Catenin Signaling Axis[J]. Frontiers in pharmacology,2018,8(JAN):960.
APA	Dai, Shuang.,Yan, Yuanliang.,Xu, Zhijie.,Zeng, Shuangshuang.,Qian, Long.,...&Gong, Zhicheng*.(2018).SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3 beta/beta-Catenin Signaling Axis.Frontiers in pharmacology,8(JAN),960.
MLA	Dai, Shuang,et al."SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3 beta/beta-Catenin Signaling Axis".Frontiers in pharmacology 8.JAN(2018):960.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。